• Explore /
  • Poster
  • / Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in patients (pts) with high body mass index (BMI).

Abstract Video & Slides Poster

Authors

Jeanny Aragon-Ching

Jeanny B. Aragon-Ching

Inova Schar Cancer Institute, Fairfax, VA

Jeanny B. Aragon-Ching , Daniel P. Petrylak , Srikala S. Sridhar , Shilpa Gupta , Petros Grivas , Thomas Powles , Howard Gurney , Natalia Jacob , Karin Tyroller , Silke Guenther , Joaquim Bellmunt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02603432

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 600)

DOI

10.1200/JCO.2024.42.4_suppl.600

Abstract #

600

Poster Bd #

G6

Abstract Disclosures

Similar Posters

First Author: Srikala S. Sridhar

First Author: Masatoshi Eto

First Author: Norihiko Tsuchiya

First Author: Joaquim Bellmunt